LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Home・Aandelen Lijst・Atossa Genetics Inc

Atossa Genetics Inc

Gesloten

0.79 5.33

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.74

Max

0.8

Belangrijke statistieken
By Trading Economics
Inkomsten	-269K -8.7M
Werknemers	15
EBITDA	-269K -8.7M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+722.37% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-12M 96M
Vorige openingsprijs	-4.54
Vorige sluitingsprijs	0.79

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

0.7955 / 0.898 Steun & Weerstand

Atossa Genetics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 dec 2025, 21:08 UTC

Acquisities, Fusies, Overnames

Meta Platforms Buys AI-Device Maker Limitless

5 dec 2025, 19:39 UTC

Belangrijke Marktbewegers

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5 dec 2025, 19:17 UTC

Acquisities, Fusies, Overnames

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

5 dec 2025, 21:59 UTC

Acquisities, Fusies, Overnames

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5 dec 2025, 21:50 UTC

Marktinformatie

Winsten

Financial Services Roundup: Market Talk

5 dec 2025, 21:50 UTC

Acquisities, Fusies, Overnames

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5 dec 2025, 21:36 UTC

Marktinformatie

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5 dec 2025, 21:35 UTC

Acquisities, Fusies, Overnames

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5 dec 2025, 21:12 UTC

Marktinformatie

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5 dec 2025, 21:03 UTC

Marktinformatie

Winsten

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5 dec 2025, 21:01 UTC

Marktinformatie

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5 dec 2025, 20:43 UTC

Acquisities, Fusies, Overnames

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5 dec 2025, 20:43 UTC

Acquisities, Fusies, Overnames

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5 dec 2025, 20:42 UTC

Acquisities, Fusies, Overnames

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5 dec 2025, 20:01 UTC

Acquisities, Fusies, Overnames

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5 dec 2025, 19:44 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

5 dec 2025, 19:44 UTC

Marktinformatie

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5 dec 2025, 19:39 UTC

Marktinformatie

Silver Climbs to a New Record High -- Market Talk

5 dec 2025, 19:31 UTC

Acquisities, Fusies, Overnames

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dec 2025, 18:30 UTC

Marktinformatie

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5 dec 2025, 18:28 UTC

Acquisities, Fusies, Overnames

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dec 2025, 18:24 UTC

Acquisities, Fusies, Overnames

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

5 dec 2025, 18:20 UTC

Marktinformatie

Baker Hughes Reports Higher U.S. Rig Count -- Market Talk

5 dec 2025, 18:11 UTC

Marktinformatie

The Tale of Two Canadian Employment Indicators -- Market Talk

5 dec 2025, 17:48 UTC

Marktinformatie

Canadian Youth Unemployment Rate Cools -- Market Talk

5 dec 2025, 17:44 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

5 dec 2025, 17:44 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Correction to Imax Market Talk

5 dec 2025, 17:35 UTC

Marktinformatie

Canada Jobs Data Doesn't Jive With Trade Uncertainty, Indicators -- Market Talk

5 dec 2025, 17:25 UTC

Marktinformatie

Canadian Jobs Numbers May Support Rates Hikes Next Year -- Market Talk

Peer Vergelijking

Prijswijziging

Atossa Genetics Inc Prognose

Koersdoel

By TipRanks

722.37% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6.25 USD 722.37%

Hoogste 7.75 USD

Laagste 4 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Atossa Genetics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Atossa Genetics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.7955 / 0.898Steun & Weerstand

Recent bullish events outweigh bearish events.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Atossa Genetics Inc

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.